I am pretty surprised how little our market cap is for a biotech in an phase 3 trial almost  2 thirds completed and we have a paltry  150 Mil Canadian market cap,  Compared to biotech in the same space in the US , its a joke,  Esperion  has a market cap of $1.2 Bil USD almost $1.5 CAD   10 times the market cap of RVX and our EV chart is comparible upon completion and Betomace approval,

Either RVX is being manipulated down for insider accumulation on the cheap,   our management on the business side is doing a poor job to promote positively the company.  All it takes is amjor news out pubilcation to do a large article on RVX and we would see some SP appreciation, Its been done in the past